ASH Annual Meeting & Exposition: DLBCL | Conference

An expert in the treatment of diffuse large B-cell lymphoma explained some of the exciting advances in treatment and hypothesized what comes next after the 2020 ASH Annual Meeting & Exposition.

Ghobadi detailed the next steps needed to build on the results of a study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

Ghobadi explained an interesting correlation found in the results of his study presented at the 2020 ASH Annual Meeting & Exposition.

The ongoing GO29365 study of combination regimens containing polatuzumab vedotin (Polivy) for patients with relapsed or refractory diffuse large B-cell lymphoma added an additional 106 patients to confirm preliminary findings of safety and efficacy.

A recent study found a difference in preference when it came to the administration of rituximab in patients with blood cancer.

Research from a pilot trial presented at the 2020 American Society of Hematology (ASH) Annual Meeting found above average complete response and disease-free survival rates for patients with DLBCL.

The preliminary findings of the extension arm of the phase 2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin (Polivy) plus bendamustine (Bendeka) and rituximab (Rituxan) for patients with diffuse large B cell lymphoma.

Research presented at the 2020 ASH Annual Meeting may have found an alternative path forward for patients who do not respond to immunotherapy treatment for large B-cell lymphomas.

A novel ROR1-targeted antibody-drug conjugate, VLS-101, demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable safety profile in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma.

The CAR T-cell therapy axicabtagene ciloleucel demonstrated long-term disease control with rapid responses and robust CAR T-cell expansion among patients with refractory large B-cell lymphoma.